ASH 2024: High Rates of Disease Control Without Radiotherapy Observed Following Incorporation of Nivolumab in Early Stage cHL As treatment options for classic Hodgkin lymphoma (cHL) have improved, minimizing late effects while maximizing treatment efficacy has become a critical goal…
ASH 2024: Phase III Study of Glofitamab Plus Pola-R-CHP Ongoing in Patients with Previously Untreated CD20-Positive LBCL Combination therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, known as R-CHOP, is a standard first-line treatment option for patients with diffuse large…
ASH 2024: High Response Rates Observed with Loncastuximab Tesirine Plus Rituximab in High-Risk Patients with Relapsed/Refractory FL Loncastuximab tesirine (loncastuximab) is an antibody-drug conjugate used to treat certain types of B-cell lymphomas. The phase I study of loncastuximab showed promise…
ASH 2024: Poor Outcomes Observed Following Disease Progression After CD19-Directed CAR T-Cell Therapy Chimeric antigen receptor (CAR) T-cell therapies have become a standard treatment option for many patients with relapsed or refractory mantle cell lymphoma (MCL). While these therapies are…
Cancer Leadership Council Statement on Medicaid and Support for Cancer Patients A Congressional budget resolution targeting potential reductions to federal Medicaid spending is being considered by the House of Representatives this week. Medicaid is the primary program providing comprehensive health…
Care Partner vs. Caregiver: Why Language Matters in Lymphoma Support When a loved one is diagnosed with lymphoma, the individuals who support them play a crucial role in their journey. Historically, these individuals have been referred to as “caregivers,” but…
The U.S. Food and Drug Administration (FDA) Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-cell Lymphoma February 12, 2025 – On February 12, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved…
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved acalabrutinib (CALQUENCE, AstraZeneca) with bendamustine and rituximab…